A Single-Arm, Open-Label Phase II Clinical Trial Evaluating the Efficacy and Safety of Chidamide Monotherapy in Participants With Intermediate-to-High-Risk Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of bone marrow disorders that can cause low blood cell counts and may progress to acute leukemia. Treatment options for patients with intermediate-to-high-risk MDS are limited, especially for older patients or those who are not suitable for intensive chemotherapy or hypomethylating agents.
Chidamide is an oral histone deacetylase inhibitor that has shown antitumor activity in several hematologic malignancies. This study aims to evaluate the effectiveness and safety of chidamide used alone in patients with intermediate-to-high-risk MDS.
This is a prospective, single-arm, open-label phase II study conducted at a single center. Eligible participants will receive oral chidamide twice weekly and will be followed for treatment response and side effects. The results of this study may help determine whether chidamide could be a potential treatment option for patients with intermediate-to-high-risk MDS who have limited therapeutic choices.

开始日期2026-07-01

申办/合作机构

厦门大学附属中山医院（厦门中山医院、厦门市老年病康复研究所、厦门市消化疾病研究所、厦门市临床检验中心）

NCT07643636

/ Not yet recruiting临床2期IIT

A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the Treatment of Intermediate- to High-risk Fit AML Patients

This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation mechanism.

开始日期2026-06-30

申办/合作机构

东莞市人民医院（东莞市肿瘤防治中心）

NCT07635992

/ Not yet recruiting临床1期IIT

A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV

HIV viral reservoirs represent the major barrier to curing AIDS, and effectively reducing viral reservoirs in people living with HIV through different strategies has become a research priority in the HIV field.
Ipilimumab-tovorafenib monoclonal antibody injection (Aituo combination antibody, QL1706) contains two engineered monoclonal antibodies targeting PD-1 and CTLA-4. Chidamide is the first independently developed histone deacetylase inhibitor in China. This study aims to evaluate the safety and efficacy of Aituo combination antibody combined with chidamide in people living with HIV.
This study adopts a modified "1+3+3" dose-escalation design. Initially, one participant will be enrolled at dose level 1 (DL1) for safety observation. If the treatment is well tolerated, the study will proceed to a standard 3+3 design, with sequential dose escalation to DL2 and DL3.
Three dose levels are planned: DL1, the starting dose, consists of ipilimumab-tovorafenib monoclonal antibody injection at 0.3 mg/kg once every 4 weeks ± 1 day for a total of three doses, in combination with chidamide 10 mg orally twice weekly for 12 weeks. DL2 consists of ipilimumab-tovorafenib monoclonal antibody injection at 1 mg/kg once every 4 weeks ± 1 day for a total of three doses, in combination with chidamide 10 mg orally twice weekly for 12 weeks. DL3 consists of ipilimumab-tovorafenib monoclonal antibody injection at 2 mg/kg once every 4 weeks ± 1 day for a total of three doses, in combination with chidamide 10 mg orally twice weekly for 12 weeks.
During dose escalation, progression to the next dose level or discontinuation of escalation will be determined according to the occurrence of dose-limiting toxicities (DLTs). The DLT observation window is 28 days after the first dose. Participants evaluable for DLT are those who complete the observation window or experience a DLT. After completion of dose escalation, the maximum tolerated dose (MTD) will be determined based on safety and tolerability. If the MTD is not reached, DL3 will be selected as the dose for subsequent study.
After determination of the MTD or the subsequent study dose, an additional 11 participants will be enrolled at that dose level to further evaluate safety, tolerability, and preliminary efficacy. The maximum total sample size of the study will be 29 participants.

开始日期2026-06-01

申办/合作机构

浙江大学医学院附属第一医院（浙江省第一医院）

100 项与西达本胺相关的临床结果

登录后查看更多信息

100 项与西达本胺相关的转化医学

登录后查看更多信息

100 项与西达本胺相关的专利（医药）

登录后查看更多信息

2,158

项与西达本胺相关的文献（医药）

2026-08-01·MOLECULAR AND CELLULAR ENDOCRINOLOGY

Histone deacetylases inhibitor Chidamide mitigates inflammation and insulin resistance by targeting VDR in skeletal muscle cells

Article

作者: Cui, Longfei ; Zhang, Maosen ; Zhu, Meng ; Luo, Xinyu ; Zhang, Lulu ; Zhao, Yunfei ; Zhao, Jia-Mu

The pathogenesis of Type 2 diabetes mellitus (T2DM) is heavily driven by exacerbated insulin resistance and inflammation in skeletal muscle, a major site for insulin-stimulated glucose uptake. Therefore, targeting inflammation and insulin resistance within this tissue represents an effective therapeutic strategy for T2DM. While histone deacetylase inhibitors (HDACi) exhibit therapeutic potential for metabolic diseases, the specific impact of the novel HDACi, Chidamide, on regulating skeletal muscle insulin resistance remains to be elucidated. Here, we provide in vitro evidence that Chidamide mitigates skeletal muscle inflammation and insulin resistance in a palmitic acid (PA)-induced C2C12 cell model. We demonstrate that Chidamide alleviates inflammation and activates the Akt/GSK3β/AS160-mediated insulin signaling thereby promoting cell-surface localization of GLUT4 and glucose uptake. Mechanistically, PA downregulates the expression of the vitamin D receptor (VDR), contributing to the inflammatory response and impairing Akt/GSK3β/AS160-mediated insulin signaling, which ultimately inhibited GLUT4-mediated glucose uptake. Chidamide effectively alleviates these effects by upregulating VDR transcription, potentially through the augmentation of histone H3 acetylation, thereby restoring insulin sensitivity and increasing GLUT4-mediated glucose uptake. In conclusion, our findings provide a proof-of-concept for the potential utility of Chidamide as a therapeutic strategy to enhance skeletal muscle insulin sensitivity.

2026-08-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer

Article

作者: Lin, Haiyan ; Sun, Lu ; Wang, Xiujun ; Lang, Ziyan ; Zhou, Ying ; Zhang, Boyu ; Ji, Jing ; Asan, Kadirya ; Wang, Jian

In this study, we designed and synthesized a series of compounds derived from the histone deacetylase inhibitor (HDACi) Chidamide and the BET bromodomain inhibitor (+)-JQ-1. All target compounds were structurally characterized by ¹H NMR, ¹³C NMR, and high-resolution mass spectrometry (HRMS). Antiproliferative activity was assessed by an MTT assay in MDA-MB-231 (breast cancer), HeLa (cervical cancer), and HCT116 (colon cancer) cells, with chidamide and (+)-JQ-1 as reference compounds; cytotoxicity in 293 T cells was further evaluated to estimate selectivity. Results indicated that most derivatives exhibited superior activity to Chidamide, with compound 6e demonstrating the strongest inhibitory effect against MDA-MB-231 cells. The IC₅₀ values of 6e were 0.10 ± 0.02 μM (MDA-MB-231), 0.90 ± 0.17 μM (HeLa), 19.60 ± 0.90 μM (HCT116), and 70.13 ± 5.19 μM (293 T). Further assays showed that 6e inhibited colony formation, migration, adhesion, and invasion of MDA-MB-231 cells in a concentration-dependent manner. Annexin V-FITC/PI flow cytometry indicated apoptosis induction. In the chicken embryo chorioallantoic membrane (CAM) model, 6e inhibited tumor growth and angiogenesis more effectively than chidamide. In summary, 6e demonstrates promising optimization potential as a lead compound for breast cancer therapy.

2026-07-01·BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Mapping the immune landscape of PCa: From tumor microenvironment to therapeutics

Review

作者: Li, Zean ; Zhuang, Wei ; Huang, Shanhe ; Huang, Hai ; Huang, Jinxing ; Wang, Baojun ; Ou, Yuan

Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men, yet its response to immunotherapy is notably limited compared to other solid tumors. This resistance stems primarily from a highly immunosuppressive tumor microenvironment (TME), characterized by "cold" tumor features such as low mutational burden, scarce cytotoxic T cell infiltration and extensive regulatory cell populations. Building upon the "tumor ecosystem" concept, we integrate emerging insights from single-cell and spatial transcriptomics to decode the spatiotemporal heterogeneity of the PCa ecosystem. We specifically highlight the underappreciated "neural-immune-microbiome" axis-a triangular regulatory network wherein sympathetic nerves suppress T cell motility, intratumoral microbiota drive chronic inflammation, and metabolic reprogramming creates lipid-mediated immune paralysis. We further dissect how cell-type specific remodeling mechanisms, particularly TREM2+ macrophage-mediated metabolic symbiosis, drive the transition from hormone-sensitive to castration-resistant disease. Furthermore, we critically assess how standard of care (ADT, chemotherapy, radiotherapy) and emerging agents (PARPi, HDACi) reprogram the immune landscape with time-dependent, often paradoxical effects. Finally, we propose a roadmap for precision oncology, emphasizing that future success lies in "ecological editing"-biomarker-driven patient stratification and rational combination strategies to overcome the physical and biological barriers of the TME.

798

项与西达本胺相关的新闻（医药）

2026-06-12

·深圳微芯生物科技股份有限公司

高缓解、长生存、控安全丨2026 EHA 西达本胺（爱谱沙）17项研究成果发布

当地时间6月11日至14日，欧洲血液学协会年会（EHA 2026）在瑞典斯德哥尔摩盛大举行。微芯生物全球首个口服亚型选择性组蛋白去乙酰化酶（HDAC）抑制剂西达本胺（爱谱沙®）17项研究成果（8项壁报，9项在线摘要）公布。从淋巴瘤到白血病，从移植预处理到维持治疗，从老年患者到精准风险分层，17项研究以系统性、高质量的循证医学证据，全面展示了中国原创表观遗传调控药物西达本胺在血液肿瘤治疗中的广泛联合潜力、可靠安全性与生存获益。非霍奇金性淋巴瘤（NHL） 1项 T细胞淋巴瘤（TCL） 6项急性髓细胞性白血病&骨髓增生异常综合征（AML&MDS） 6项急性淋巴细胞白血病（ALL）1项基础研究 3项关于西达本胺（爱谱沙®）西达本胺（Chidamide；商品名：爱谱沙®/Epidaza®）是全球首个亚型选择性组蛋白去乙酰化酶（HDAC）抑制剂、中国首个原创抗肿瘤化学新药。该药属于表观遗传调控类药物，对肿瘤抑制性免疫微环境具有重新激活作用，可单独或联合其他药物治疗恶性肿瘤，应用前景广阔。西达本胺已纳入国家医保药品目录常规乙类管理。在中国（涵盖大陆、澳门及台湾地区）获批外周T细胞淋巴瘤、乳腺癌、弥漫大B细胞淋巴瘤等适应症；在日本获批成人T细胞白血病和外周T细胞淋巴瘤。与此同时，西达本胺正全面推进纵深管线，在中国及海外开展滤泡辅助T细胞表型外周T细胞淋巴瘤III期、结直肠癌III期、黑色素瘤III期等多项临床研究，其联合肿瘤免疫疗法（HDACi+IO）的策略在多个瘤种中持续验证，下一代HDACi+IO药物也正在开发中。往期推荐西达本胺DEB研究新闻发布会在京举行西达本胺DEB研究荣登JAMA 胰岛素抵抗白皮书正式发布

2026-06-11

·淋巴瘤之家086

复发/难治外周T细胞淋巴瘤新选择：双靶点抑制剂HZ-H08905 III期临床试验招募患者 | 临床试验

外周T细胞淋巴瘤（PTCL）复发或难治后，治疗选择本就有限。目前国内二线常用方案之一是西达本胺（HDAC抑制剂），但并非所有患者都能从中获益，耐药或进展后往往陷入无药可用的困境。现在，一项全新机制的III期临床研究正在为这类患者提供一个新的、可能更优的选项——HZ-H08905单药对比西达本胺单药治疗复发/难治外周T细胞淋巴瘤随机、双盲、多中心的III期临床研究正在招募淋巴瘤患者，小编整理出来供大家参考。试验介绍本研究为随机、双盲双模拟、平行分组、多中心的期临床试验，用于评估HZ-H08905（ CK1ε/PI3Kδ 双靶点抑制剂）对比西达本胺在复发/难治外周T细胞淋巴瘤(R/R PTCL)中的疗效和安全性。主要入选标准年龄≥18周岁(包含边界值)，性别不限。经组织病理学确诊的复发/难治性外周T细胞淋巴瘤(PTCL)。既往至少接受过一线系统性治疗的复发/难治受试者(需包括蔥环类药物，对于CD30阳性的ALCL还需包括维布妥昔单抗)。 ECOG评分0~2分;预计生存期≥3个月至少有1个可测量病灶;可测量病灶定义为:长径>1.5cm的淋巴结病灶或长径>1.0cm的结外病灶,并且FDG-PET阳性病变。有良好的器官功能水平，自愿参加，依从性好。主要排除标准成熟T细胞和NK细胞白血病;原发性皮肤T细胞淋巴瘤;肠道T细胞和NK细胞淋巴增殖性疾病与淋巴瘤;肝脾T细胞淋巴瘤;EBV阳性NK细胞及T细胞淋巴瘤或淋巴瘤白血病期(骨髓检查淋巴瘤细胞比例≥20%)或中枢神经系统受累或并发噬血细胞综合征患者。既往接受过组蛋白去乙酰化酶抑制剂(如西达本胺)治疗(持续用药不足2周者可在研究者谨慎评估后入组)。既往接受过PI3K抑制剂治疗(对短期非正规使用者，经研究者评估可以考虑入组)。详情咨询扫码添加丁丁，备注：双靶点抑制剂。了解更多临床试验信息手机应用商店中搜索“淋巴瘤之家”，或长按识别下方二维码，下载淋巴瘤之家app，找你感兴趣的临床试验消息，或者联系对应亚型的群主咨询临床试验信息。 END 编辑：关关 | 排版：悠然 | 审核：关关声明：本文中涉及的信息仅供淋巴瘤病友及家属交流参考，不作为用药推荐，具体诊疗方案请遵从专业医生的意见或指导。关于淋巴瘤之家淋巴瘤之家是中国唯一覆盖全国范围的淋巴瘤患者组织，是国际抗癌联盟、国际淋巴瘤联盟、国际患者联盟、国际慢淋倡导网络的成员，以及国际华氏巨球蛋白血症基金会的合作伙伴。 2011 年由霍奇金淋巴瘤康复病友洪飞创立，其多数工作人员为有过淋巴瘤经历的患者和家属，以“让患者少走弯路，让治愈加速到来”为使命。在众多淋巴瘤权威医学专家，患者、学者、创新药研发企业们的支持下，淋巴瘤之家成为了被患者认可、提供暖心守护与贴心陪伴的家园。2026年，注册用户已经超过 16万人，每年新增用户超过 2 万人。关注一下抗瘤少走弯路

2026-06-10

·中大血液

EHA 2026中国之声丨葛峥教授团队20项研究成果亮相！聚焦创新药物与机制探索，开拓血液肿瘤治疗新路径

以下报道转载自CCMTV血液频道（2026年6月4日 15:04 北京）引言第31届欧洲血液学会年会（EHA 2026）将于2026年6月11—14日在瑞典首都斯德哥尔摩举行。作为全球血液学领域最具影响力的国际学术盛会之一，本届大会将围绕血液系统疾病的基础研究突破、转化医学进展、临床诊疗革新及精准医疗探索展开深度交流，而创新药物研发与临床应用始终是推动血液肿瘤诊疗水平提升的核心驱动力。从传统化疗到精准靶向治疗，从表观遗传调控到新型蛋白降解技术，不同作用机制的药物不断涌现，为解决复发难治、高危耐药等临床难题提供了更多可能。东南大学附属中大医院葛峥教授团队长期深耕血液肿瘤精准药物治疗领域，始终以临床未满足需求为导向，围绕表观遗传调控、激酶信号通路抑制、蛋白降解等前沿药物方向，系统开展从分子机制探索到临床疗效验证的全流程研究。在本次大会上，葛峥教授团队共有20项研究成果成功亮相，覆盖急性髓系白血病、急性淋巴细胞白血病、骨髓增生异常肿瘤（MDS）、外周T细胞淋巴瘤、多发性骨髓瘤等多种难治性血液系统疾病。CCMTV特别梳理葛峥教授团队本次EHA 2026入选研究的核心进展方向，系统呈现其在血液肿瘤精准治疗领域的前沿探索成果与深度临床实践思考。一、表观遗传调控类药物以国产HDAC抑制剂西达本胺为核心，探索其在不同血液肿瘤中的单药及联合治疗潜力。摘要号：PS1586 题目：SYNERGISTIC EFFICACY OF HDACI CHIDAMIDE WITH GL-V9 BY SUPPRESSING MYBL2 EXPRESSION IN ACUTE MYELOID LEUKEMIA（HDAC抑制剂西达本胺联合GL-V9通过抑制MYBL2表达在急性髓系白血病中发挥协同效应）汇报类型：Poster Presentation 第一作者：毕亚珍通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB3902 题目：GOLIDOCITINIB、MITOXANTRONE HYDROCHLORIDE LIPOSOME、CHIDAMIDE AND PREDNISONE (GO-MCP) IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA:A REAL-WORLD RETROSPECTIVE STUDY（戈利昔替尼、盐酸米托蒽醌脂质体、西达本胺和泼尼松（GO-MCP）方案治疗复发/难治性外周T细胞淋巴瘤：一项真实世界回顾性研究）汇报类型：Publication Only 第一作者：徐璐璇通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB2541 题目：ONCOGENIC ROLE AND DRUG SENSITIVITY OF A NEW IKZF1 MUTATION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA（新型IKZF1突变在B细胞急性淋巴细胞白血病中的致癌作用及对西达本胺联合方案的药物敏感性）汇报类型：Publication Only 第一作者：项慧敏通讯作者：葛峥单位：东南大学附属中大医院二、小分子激酶抑制剂聚焦CK2、BTK等关键致癌激酶靶点，探索单药及多靶点联合治疗的机制与疗效。 1. CK2抑制剂摘要号：PS1523 题目：SYNERGISTIC EFFECT OF COMBINED CK2 AND XPO1 INHIBITION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA: MECHANISM AND THERAPEUTIC POTENTIAL（CK2与XPO1联合抑制在急性髓系白血病临床前模型中的协同效应：机制与治疗潜力）汇报类型：Poster Presentation 第一作者：龙会登通讯作者：葛峥单位：东南大学附属中大医院摘要号：PS1464 题目：EFFICACY OF BIOMIMETIC NANODRUG CX4945 IN B-ALL PATIENT-DERIVED XENOGRAFT MOUSE MODEL（仿生纳米药物CX4945在B-ALL患者来源异种移植小鼠模型中的疗效）汇报类型：Poster Presentation 第一作者：王艳通讯作者：葛峥单位：东南大学附属中大医院摘要号：PF350 题目：THERAPEUTIC EFFECT OF CX-4945 COMBINED WITH XPO1 INHIBITOR BY TARGETING AMINO ACID METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA（CX-4945联合XPO1抑制剂靶向氨基酸代谢在T细胞急性淋巴细胞白血病中的治疗效应）汇报类型：Poster Presentation 第一作者：韩旗通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB2540 题目：SYNERGISTIC THERAPEUTIC EFFICACY OF CDK9 INHIBITOR WITH CX-4945 BY REPRESSING ASNS TRANSCRIPTION IN HIGH-RISK B-ALL（CDK9抑制剂联合CX-4945通过抑制ASNS转录在高危B-ALL中发挥协同治疗效果）汇报类型：Publication Only 第一作者：项慧敏通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB2539 题目：THERAPEUTIC EFFECT OF TARGETING CASEIN KINASE II / PLK1 ONCOGENIC SIGNALING IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA（靶向酪蛋白激酶II/PLK1致癌信号通路在T细胞急性淋巴细胞白血病中的治疗效应）汇报类型：Publication Only 第一作者：韩旗通讯作者：葛峥单位：东南大学附属中大医院 2. BTK抑制剂摘要号：PB3739 题目：ZRTD, A CHEMO-LIGHT REGIMEN, CONFERS FAVORABLE EFFICACY AND SAFETY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA（ZRTD（一种轻度化疗方案）用于初诊原发性中枢神经系统淋巴瘤老年患者的疗效与安全性研究）汇报类型：Publication Only 第一作者：张孝平通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB3790 题目：COMPARISON OF THE EFFICACY OF ZANUBRUTINIB PLUS RITUXIMAB-BASED REGIMEN AS FIRST-LINE TREATMENT IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA（泽布替尼联合利妥昔单抗方案一线治疗初治弥漫大B细胞淋巴瘤的疗效比较研究）汇报类型：Publication Only 第一作者：赵明钰通讯作者：葛峥单位：东南大学附属中大医院三、蛋白降解相关药物聚焦传统蛋白酶体抑制剂的临床应用优化与新型分子胶降解剂的前沿探索，为血液肿瘤无化疗治疗提供新的靶点选择。摘要号：PF850 题目：FIRST-LINE USE OF CARFILZOMIB-BASED REGIMENS IMPROVES SURVIVAL OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMAS: A REAL-WORLD RETROSPECTIVE STUDY（一线应用卡非佐米方案改善伴有髓外浆细胞瘤的新诊断多发性骨髓瘤患者生存：一项真实世界回顾性研究）汇报类型：Poster Presentation 第一作者：菅子莹通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB2565 题目：A NOVEL GSPT1 DEGRADER 329 EXHIBITS IN VITRO EFFICACY IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA（新型GSPT1降解剂329在T细胞急性淋巴细胞白血病中的体外疗效研究）汇报类型：Publication Only 第一作者：李梦月通讯作者：葛峥单位：东南大学附属中大医院四、黄酮类化合物聚焦天然来源黄酮衍生物与合成类黄酮靶向药物在血液肿瘤治疗中的应用潜力，为血液肿瘤治疗提供了结构新颖、机制独特的新方向。摘要号：PF464 题目：THERAPEUTIC ROLE OF GLV8 BY TARGETING GPR84 IN VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA（靶向GPR84的GLV8在维奈克拉耐药急性髓系白血病中的治疗作用）汇报类型：Poster Presentation 第一作者：丁洋洋通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB2556 题目：GL-V9, A NOVEL NATURAL FLAVONOID DERIVATIVE, DISPLAYING AN ANTI-TUMOR EFFECT IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA（新型天然黄酮类衍生物GL-V9在T细胞急性淋巴细胞白血病中的抗肿瘤作用）汇报类型：Publication Only 第一作者：李梦月通讯作者：葛峥单位：东南大学附属中大医院五、预后、基础机制与支持治疗研究聚焦血液肿瘤精准预后、分子机制与支持治疗领域，为临床诊疗决策与患者全周期管理提供科学支撑。 1. 预后分析摘要号：PF674 题目：BEYOND STATIC BASELINES: PREDICTIVE VALUE OF DYNAMIC KARYOTYPE EVOLUTION FOR DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN MYELODYSPLASTIC NEOPLASMS（超越静态基线：动态核型演化对骨髓增生异常肿瘤疾病进展及白血病转化的预测价值）汇报类型：Poster Presentation 第一作者：王滢通讯作者：葛峥单位：东南大学附属中大医院摘要号：PF677 题目：BLAST DEMONSTRATES HIGHER PROGNOSTIC ACCURACY FOR SURVIVAL THAN CPSS IN CHINESE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA（在中国慢性粒-单核细胞白血病患者中，BLAST评分对生存的预后准确性高于CPSS）汇报类型：Poster Presentation 第一作者：严欣1 冯格格2 通讯作者：许书倩2 葛峥1（最后通讯作者）单位：1东南大学附属中大医院，2山东大学齐鲁医院摘要号：PF535 题目：DNMT3A R882 HOTSPOT MUTATION DEFINES A HIGH-RISK SUBGROUP IN TREATMENT-NAÏVE AML IRRESPECTIVE OF CO-MUTATION STATUS（DNMT3A R882热点突变定义初治AML中不受协同突变状态影响的高危亚组）汇报类型：Poster Presentation 第一作者：赵明钰通讯作者：葛峥单位：东南大学附属中大医院摘要号：PB2734 题目：EFFECT OF CONCOMITANT WT1 OR DNMT3A MUTATIONS ON THE PROGNOSIS OF PATIENTS WITH CEBPA-MUTATED ACUTE MYELOID LEUKEMIA（合并WT1或DNMT3A突变对CEBPA突变急性髓系白血病患者预后的影响）汇报类型：Publication Only 第一作者：贾一帆通讯作者：葛峥单位：东南大学附属中大医院 2. 分子机制摘要号：PF456 题目：EZH2 MODULATES HELLS EXPRESSION THROUGH EPIGENETIC ENHANCER ACTIVATION IN ACUTE MYELOID LEUKEMIA（EZH2在急性髓系白血病中通过表观遗传增强子激活调控HELLS表达）汇报类型：Poster Presentation 第一作者：杨婵通讯作者：葛峥单位：东南大学附属中大医院 3. 支持治疗摘要号：PB4449 题目：DEVELOPMENT OF BALANCED PSYCHOTHERAPY FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NOVEL MODEL BASED ON EASTERN PHILOSOPHY（针对恶性血液病患者的平衡心理治疗方案开发：基于东方哲学的新范式）汇报类型：Publication Only 第一作者：邓肖祎通讯作者：袁勇贵，葛峥（最后通讯作者）单位：东南大学附属中大医院东南大学附属中大医院血液科自 1976 年创立以来，步履坚实，稳步攀升。“十三五”、“十四五”是血液科腾飞发展的十年，科室实现了从临床专科到区域引领、从技术突破到体系构建的跨越式发展。作为江苏省血液区域医疗中心，江苏省卫生健康科教能力提升工程血液病学医学重点学科建设单位，以及江苏省临床重点专科，科室秉持 “临床 + 科研双轮驱动”、“多学科和跨学科交叉融合”发展模式，建成涵盖八大核心功能定位的血液病中心，构建起临床诊疗、基础研究、转化创新无缝衔接的学科发展新格局。科室聚焦急性白血病、MDS、淋巴瘤、多发性骨髓瘤等优势病种，开展国际和国内多中心新药临床试验、制定和开展创新性“中大方案”、牵头开展注册临床研究，打造省内领先、国内知名的特色诊疗品牌，学科引领成果显著。从学科初创到行业引领，五十余载风雨兼程，东南大学附属中大医院血液科始终以患者为中心、以创新为驱动，在医教研道路上持续攀登。未来，科室将秉持“精医崇德、守正创新”理念，建设具有中大特色的江苏省血液区域医疗中心，以更高水平诊疗技术、更优质医疗服务、更深厚科研积淀，守护生命健康，为血液病患者点亮希望，为我国血液病医学事业发展持续贡献中大力量！

100 项与西达本胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	西达本胺	L01XX	DB06334

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	中国	深圳微芯生物科技股份有限公司	2024-04-24
成人T细胞白血病/淋巴瘤	日本	Meiji Seika Pharma Co., Ltd.	2021-06-23
HR阳性/HER2阴性乳腺癌	中国	深圳微芯生物科技股份有限公司	2019-11-20
外周T细胞淋巴瘤	中国	深圳微芯生物科技股份有限公司	2014-12-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
错配修复功能正常的微卫星稳定型结肠癌	临床3期	中国	深圳微芯生物科技股份有限公司	2024-12-06
不能切除的大肠癌	临床3期	中国	深圳微芯生物科技股份有限公司	2024-12-06
转移性微卫星稳定结直肠癌	临床3期	中国	中山大学	2023-03-01
微卫星稳定型结直肠癌	临床3期	中国	中山大学	2023-03-01
脑转移瘤	临床3期	美国	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	日本	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	澳大利亚	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	奥地利	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	比利时	Huyabio International LLC	2021-08-12
脑转移瘤	临床3期	巴西	Huyabio International LLC	2021-08-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06979908 (ASCO2026)	临床2期	结直肠癌 Microsatellite stable (MSS)	9	Fruquintinib+sintilimab+chidamide (Microsatellite stable metastatic colorectal cancer)	獵淵鏇積壓餘窪襯遞夢(膚鬱蓋遞壓鹽齋鏇衊淵) = 膚淵憲餘廠蓋選淵簾觸淵網蓋餘壓構襯積築淵 (憲壓選壓膚憲衊鹹網憲 ) 更多	积极	2026-05-29
ChiCTR2300077213 (C-ooperate/SCOG-C001, ASCO2026)	临床2期	晚期结直肠腺癌三线	30	Regorafenib 120 mgChidamide 20 mgFruquintinib 5 mg + Regorafenib 120 mgChidamide 20 mgg/kgFruquintinib 5 mg + Regorafenib 120 mgChidamide 20 mg mg or Fruquintinib 5 mg (pMMR/MSS + Advanced Colorectal Cancer)	獵廠鹽鹹膚選餘蓋築餘(構膚鬱築齋網鑰淵構簾) = 壓願積壓構蓋鹽簾窪衊膚醖蓋網夢襯網鏇築膚 (糧遞淵鑰積鬱憲鹹蓋齋, 2.4 ~ 30.2) 更多	积极	2026-05-29
NCT04231448 (Pubmed \| JAMA)	临床3期	弥漫性大B细胞淋巴瘤一线	423	Tucidinostat + R-CHOP	餘憲鹽築繭範衊鏇構衊(糧積遞築壓顧範鹹網積) = 淵鹹壓衊鹹夢繭齋廠遞窪築遞鬱艱艱構積網襯 (憲餘鹹糧遞積鏇築遞網 ) 更多	积极	2026-05-19
NCT04231448 (Pubmed \| JAMA)	临床3期	弥漫性大B细胞淋巴瘤一线	423	Placebo + R-CHOP	餘憲鹽築繭範衊鏇構衊(糧積遞築壓顧範鹹網積) = 顧夢鹽築簾選顧餘鑰醖窪築遞鬱艱艱構積網襯 (憲餘鹹糧遞積鏇築遞網 ) 更多	积极	2026-05-19
NCT05141357 (HBI-8000, CTgov)	临床2期	非小细胞肺癌	5	HBI-8000+pembrolizumab	顧壓積鑰夢壓鑰獵餘簾 = 鏇遞製鹹網鹽鬱廠壓襯獵製鏇簾觸齋選壓廠願 (淵鏇壓鑰構鏇糧廠蓋壓, 鹽顧蓋齋蓋積齋鹽齋繭 ~ 鏇繭簾鑰糧壓積選範糧) 更多	-	2025-12-24
SABCS2025	临床2期	HR-positive \| HER2-negative	30	Chidamide + Fulvestrant	遞蓋餘淵壓製壓構鬱鬱(觸壓餘齋製鏇糧鑰顧鑰) = 鏇鬱顧積製襯憲築膚範夢蓋鏇壓齋艱衊鹹願衊 (繭壓構醖餘齋簾餘醖襯 )	积极	2025-12-10
NCT03838354 (ASH2025)	临床1/2期	免疫性血小板减少症	61	Chidamide 2.5 mg	遞艱遞窪獵觸網選壓壓(鏇選夢簾繭憲醖膚鏇願) = 窪選網鹽壓觸憲糧鹹構獵廠製鏇築膚選淵壓顧 (繭觸憲憲壓鹹鏇繭夢遞 ) 更多	积极	2025-12-06
NCT03838354 (ASH2025)	临床1/2期	免疫性血小板减少症	61	Chidamide 5 mg	遞艱遞窪獵觸網選壓壓(鏇選夢簾繭憲醖膚鏇願) = 餘觸餘構憲餘醖憲觸積獵廠製鏇築膚選淵壓顧 (繭觸憲憲壓鹹鏇繭夢遞 ) 更多	积极	2025-12-06
ASH2025	N/A	原发性中枢神经系统淋巴瘤	11	Chidamide + methotrexate + ifosfamide + etoposide + doxorubicin liposomes + dexamethasone	淵淵醖觸繭糧夢窪淵糧(餘遞衊顧餘糧鑰顧簾膚) = The most common adverse events were hypocytosis and gastrointestinal symptoms. Grade 4 hematological toxicity occurred in 2 patients. No patients died of toxicity. 鹽淵製顧製觸糧觸鑰鑰 (淵鬱襯壓獵範願獵範廠 ) 更多	积极	2025-12-06
NCT05367856 (ASH2025)	临床2期	外周T细胞淋巴瘤	23	Chidamide+BEAM+ASCT	襯顧鏇鑰蓋獵選繭積構(獵蓋廠壓醖範醖積鏇構) = 簾構醖範窪構選構衊鑰鏇齋蓋鑰蓋襯壓顧選餘 (鹹廠鏇範蓋繭襯淵遞襯, 72.9 ~ 99.4) 更多	积极	2025-12-06
NCT04231448 (DEB, ASH2025)	临床3期	弥漫性大B细胞淋巴瘤 MYC \| BCL2	423	Tucidinostat plus R-CHOP	醖艱膚鏇獵遞蓋壓廠構(鹹範繭鏇鬱夢鹽窪醖簾) = 網廠鹽壓蓋鏇製範網糧蓋鏇鬱獵齋淵鹹積願鏇 (夢膚顧積積艱鹽窪憲窪 ) 更多	积极	2025-12-06
NCT04231448 (DEB, ASH2025)	临床3期	弥漫性大B细胞淋巴瘤 MYC \| BCL2	423	Placebo plus R-CHOP	醖艱膚鏇獵遞蓋壓廠構(鹹範繭鏇鬱夢鹽窪醖簾) = 積鹽築淵憲鹹網艱積淵蓋鏇鬱獵齋淵鹹積願鏇 (夢膚顧積積艱鹽窪憲窪 ) 更多	积极	2025-12-06
NCT05976997 (ASH2025)	临床2期	免疫母细胞性淋巴结病一线	12	Duvelisib + Chidamide + CHOP chemotherapy	廠鹽壓積製壓製範壓繭(獵衊憲醖鹹夢壓壓淵餘) = mainly hematological toxicity, including leucopenia (41.7%)and neutropenia (41.7%), as well as infections including lung infections 33.3% 夢壓範廠顧衊醖衊選製 (壓築簾範築觸壓鑰齋簾 ) 更多	积极	2025-12-06